DNA methylation profiling upon treatment with NTX-301 or decitabine in AML cells. DNA methylation profiling upon treatment with NTX-301 or decitabine in AML cells

A novel hypomethylating agent NTX-301 is a promising therapeutic agent for AML patients. To examine its mechanisms of action, we produced methylome data upon treatment with NTX-301 or decitabine (DAC) in MV4-11 cell line. Overall design: Leukimia cells (MV4-11 and HL-60) were cultured using the RPMI1640 medium. Cells were plated on 10cm dishes at the day before drug treatment, and DMSO, NTX-301 (60nM), and DAC (60nM) were treated during 48h. After extracting genomic DNA and assessing DNA QC,

新型低甲基化剂（hypomethylating agent）NTX-301是一款颇具前景的急性髓系白血病（Acute Myeloid Leukemia, AML）治疗药物。为探究其作用机制，我们在MV4-11细胞系（cell line）中经NTX-301或地西他滨（decitabine, DAC）处理后，获取了甲基化组（methylome）数据。整体实验设计：采用RPMI1640培养基培养白血病细胞（MV4-11与HL-60）；于药物处理前一日将细胞接种于10cm培养皿中，随后分别以二甲基亚砜（DMSO）、60nM NTX-301及60nM DAC处理细胞48小时；完成基因组DNA提取与DNA质量控制（Quality Control, QC）后